EarlyCDT-Lung: a simple blood test for the early detection of lung cancer

  • Our clinically validated blood test for lung cancer measures a panel of 7 autoantibodies associated with small cell and non-small cell lung cancers at all stages of disease
  • EarlyCDT-Lung can detect lung cancer 4 years or more before diagnosis1,2. Test performance has been optimised for ‘rule-in’ use in conjunction with CT scanning
  • EarlyCDT-Lung can be used to assess the malignancy risk of CT-detected pulmonary nodules as a ‘rule-in’ test for lung cancer3,5
  • It can also be used in conjunction with CT scanning to ‘rule-in’ and assess the risk of lung cancer in asymptomatic patients at increased risk of the disease4,5,6. It is not a ‘rule-out’ test.
  • EarlyCDT-Lung can be billed in the US to most major payors. It is currently self-pay elsewhere in the world
  • The test may only be ordered by physicians. It requires a small blood sample either drawn by a phlebotomist or by the patient using a simple finger stick self-draw kit
  • EarlyCDT-Lung test is run in our CLIA-certified laboratory in the US
  • It can also be run in hospital laboratories outside the US using our proprietary CE and ISO 13845:2012 marked kit

1 Zhong L, et al. Profiling tumour-associated antibodies for early detection of non-small cell lung cancer. J Thor Oncol 2006; 1:513-519.
2 Jett J, et al. Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort. J Thor Oncol 2017; 12(11):S2170.
For patients with one or more nodules the combined test results ‘Moderate Level’ and ‘High Level’ have Accuracy 83% and PPV 59% (1 in 1.7). For a ‘High Level’ test result: Accuracy 84% and PPV 1 in 1.3 (78%). (Based on lung cancer prevalence of 20%)
In asymptomatic patients at increased risk5: Accuracy 92%, PPV 10% (1 in 10);  for combined Moderate and High Level results.  For a High Level test result Accuracy 97% and PPV 1 in 5 (20%). (Based on lung cancer prevalence of 1.2% increased by a conservative 50% to account for the “look forward” ability for autoantibodies to be detected prior to a cancer being detectable by imaging1)
5 Combined Moderate and High Level test result: Specificity 93%; Sensitivity 41%. High Level test result: Specificity 98% and Sensitivity 28%
6 Increased risk is defined as 20+ pack years and 50+ years, or 40+ years and another risk factor


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept